Comparing the effects of echinophora-platyloba, fennel and placebo on pre-menstrual syndrome.
Premenstrual syndrome (PMS) is characterized by a number of behavioral, psychological and physical symptoms recurring cyclically during the luteal phase of the menstrual cycle and they disappearing in the first days of menstruation (1).
More than fifty symptoms have been found which are contributed to PMS. The most common symptoms of PMS are irritability, mood swings, anxiety, depression, breast tenderness, bloating and headache (2, 3). Due to the variety and severity of the symptoms, it is difficult to estimate the exact prevalence of PMS, but previous studies have reported a 20-90% estimate (4). With the limited diagnostic criteria, the prevalence of PMS reaches to 2-6% in reproductive age (1). Sometimes premenstrual syndrome and related behavioral symptoms are legally important and are considered as a defense against criminal acts and sometimes they can lead to murder (5-7). A study reported that PMS caused a 27.5% reduction in women's work efficacy and 22% had problems in working relationship. This study also demonstrated that PMS led to problems with husband (83%), problems with children (61%) and social relationships disorders (41.5%) (8).
The etiology of PMS is largely unclear and different theories have been suggested, including hormone imbalances, hypoglycemia, hyperprolactinaemia, psychological causes, reduced endorphins release, ovary infections, deficiency of essential fatty acids, dysfunction in acid and base balance, imbalances in prostaglandins, vitamin and mineral deficiencies (9-12).
Pathophysiology of PMS is unknown and different therapeutic protocols have been suggested for its treatment. Non-pharmacological treatments include changes in dietary habits, reduction in salt intake, reduction in animal fat consumption, exercise, stress reduction and availability of support systems. Pharmacological treatments include GnRH analogues, spironolactone, danazol, alprazolam, mephenamic acid, gamalinoleaic acid, and fluoxetine (13-15).
In recent years, use of herbs has been considered in the treatment of premenstrual syndrome (16-19). Echinophora-platyloba (E. platyloba) and Foeniculum vulgare (Fennel) are herbs that are traditionally used for menstrual disorders. Echinophora platyloba belongs to Umbelliferae family and consists of four species including E. cinerea, E. platyloba, E. orientalis and E. sibthorpiana. The two aforesaid herb species are exclusive of Iran (20). E. platyloba species is known by different local names of Khoshariz, Tigh Touragh, Tigh Masti, Khoshandar, Kouzang, Tanghez or Khousharouz. This plant is a pasture plant used for flavoring foods, cheese and yoghurt (20, 21). Sadraei et al (20) reported that E. platyloba extract reduced the ileum contractions in rats. Anti-fungal effects of E. platyloba has been depicted on a number of common dermatophytes (21). The anti-candida effects of this plant was compared with amphotericin by Mahbobi et al. (22) and it was shown that this plant was effective in the treatment of candida albicans.
Fennel (Foniculmn vulgare) has been shown to have anti-inflammatory, anti-spasmodic, analgesic, diuretic, laxative, carminative and expectorant effects. In addition, because of its antioxidative effects, it is also useful for digestive and nervous disorders (23-25).
Torke Zahrani, et al (26) reported that fennel extract reduced the severity of dysmenorrhea. The effects of fennel and Mephenamic acid was studied on dysmenorrhea and it was demonstrated that both drugs reduced dysmenorrhea compared to placebo (27). Fennel essence can reduce the frequency and intensity of contractions in rat uterus (28). To the best of our knowledge, the effects of echinophora-platyloba and fennel extracts on premenstrual syndrome (PMS) has not been reported yet. The purpose of the present study was to compare the effects of echinophora-platyloba and fennel against placebo on premenstrual syndrome in the students of Shahrekord University of Medical Sciences in Iran.
This single-blind randomized clinical trial study was done on 250 female university students aged 18-25 years in Shahrekord University of Medical Sciences in Iran. The Ethics Committee approved the study (No. 352.87-1-3 on 12.5.2008) and the study was registered at the Iranian Registry of Clinical Trials and the identifier being IRCT 138810263078N1.
The participants were requested to fill the Daily Record of Severity of Problem (DRSP) two cycles before the intervention and then the severity of premenstrual syndrome was evaluated for all subjects. The daily record of severity of problem form is a standard tool for detecting the intensity of PMS and its validity and reliability have been approved by Borenstein and et al (29). This form determines the severity of PMS using five items, including: anxiety symptoms (tension, emotional changes, irritation, reduction in concentration and fear), depressive symptoms (depression, hopelessness, amnesia, crying, dizziness, mood disorders, sleep disorders, isolation and loss of interest to daily activities), emotional symptoms (headache, sweating, hot-flushes, increased appetite, heart palpitation, fatigue, reduced energy, and inability to do the daily activities), fluid and electrolyte retention symptoms (increases in weight, edema, breast tenderness, backache, abdominal cramps and pain in muscles and joints) and somatic symptoms (acne, urinary frequency, constipation and inflammation of nose)] (29). Based on the DRSP form, scores ranging from 0 to 4 were allocated to evaluate the severity of symptoms as it follows:
0: absence of symptoms, 1: mild (the individual seldom has problems in daily activities), 2: moderate (the individual has problems in maintaining daily activities, but can go to work or school), 3: severe symptoms (the individual is not able to do daily activities) and 4: very intense (the individual is confined to bed). Considering the purpose of the present study, the students with moderate and severe PMS were selected for the intervention.
All the students were also asked about their menstrual patterns; such as duration of menstruation, menstrual interval, dysmenorrhea, familial history of PMS and use of drugs for the reduction of PMS. Students with pelvic inflammatory disease (PID), any chronic diseases, drug use or with any stressor factors were excluded from the study. Finally, ninety students with the highest PMS scores, were selected and they were randomly assigned into three equal groups. The first group received echinophora-platyloba extract, the second group received fennel extract and the placebo group received strile water. The amount of the given extracts and the placebo was 30 drops, every 8 hours, 3 days before until 3 days after the onset of menstrual bleeding. The subjects completed the DRSP form at the end of their first and second menstrual cycles. After the interventions, the severity of PMS was evaluated again. The students were blind about the kind of drug throughout the study. Data was analyzed by Dunn, Kruskal-Wallis and Pearson correlation tests, using SPSS and a p<0.05 was considered significant.
From the total number students who participated in the study, 4 persons in the echinophoraplatyloba group, 2 persons in the fennel group and 3 persons in the placebo group did not complete the study. The demographic data of the students have been presented in Table 1. As shown in the table, no significant differences were observed for age, body mass index, age at menarche, age at dysmenorrhea onset and duration of menstruation between the three groups. In addition, menstrual cycle intervals and family histories of PMS were similar among the groups.
As shown in Table 2, there were no significant differences regarding the total PMS scores among three groups before the intervention (P=0.58), but differences were significant after the intervention (P=0.009). Statistical analysis demonstrated that the total premenstrual syndrome scores has been reduced upon the treatments in three groups (P<0.001). It means that echinophora-platyloba, fennel and placebo reduced the severity of PMS, but the effects of echinophora-platyloba was more significant (Table 2). When the effects of echinophora-platyloba was compared with fennel extract, there was no significant differences between the two extracts (P=0.08). There were no significant correlations between the age and body mass index of the individuals with symptoms of PMS before and after the intervention (P>0.05).
The findings of this study showed that echinophora-platyloba and fennel extracts, as well as placebo, reduced the intensity of premenstrual syndrome in students and the effects of the two extracts were more significant than these of placebo.
Echinophora-platyloba is one of the four species in Iran (20) which is also used for food. Anti-microbial and anti-fungal effects of echinophora sibthorpiana have been reported before (22, 23). In addition, Sadraei et al. showed that echinophora sibthorpiana extract reduces the rat ileum contractions in vitro (20). A previous study which was carried out on the echinophora platyloba, revealed that this herb contains elements such as saponins, alkaloids and flavonoids. Saponines are elements with toxic effects (30). As far as we know, the effects of echinophora platyloba and fennel extracts on premenstrual syndrome have not been studied yet. Previous findings from different medicinal plants have shown that use of herbs is effective in the luteal phase of the menstrual cycle and does not need to be used throughout the cycle (31). In the present study, the effects of echinophora platyloba and fennel extrats were investigated in the luteal phase too.
Our findings indicated that during the two cycles before the intervention, the severity of PMS was similar in the three study groups, but after the intervention the differences were significant. It means that, echinophora platyloba had the highest and placebo had the lowest effects in the reduction of PMS symptoms. Considering the effects of age, BMI, age at menarch, and age at dysmenorrhea on premenstrual syndrome, since the participants were randomely allocated to each group and there was not a significant difference in these variables between the groups, and also the Pearson correlation test did not show a significant correlation between premenstrual syndrome and these variables.
Among the five classifications of PMS symptoms, which include anxiety, depression, emotional, fluid and electrolyte retention and somatic symptoms, the highest effect was seen on anxiety and depressive symptoms. Aghajani and co-workers reported that the Vit-agnus castus can reduce somatic and psychological symptoms (32). Other studies reported that medicinal plants could reduce the severity of PMS up to 45%- 70% (8, 32). In comparing the effects of echinophora platyloba and fennel extracts, we found that both plants had similar effects in reducing the intensity of PMS. Psychological effects of placebo have been reported by previous studies (33) and the effect attributed to placebo in our study may also be due to these effects.
Echinophora platyloba and fennel extracts, as well as placebo, reduced the severity of premenstural syndrome. The effects of Echinophora platyloba and fennel were similar and both extracts were effective on symptoms of anxiety and depression. More studies with bigger sample sizes are needed for the use of echinophora platyloba and fennel essences, instead of their extracts, to be suggested for PMS treatment.
This work was financially supported by the research council of the Shahr-e-kord University of Medical Sciences. Hereby, we thank the vicechancellor for Research of the University, Barriage Essence Company and the students who participated in this study.
(1.) Tschudin S, Bertea PC, Zemp E. Prevalence and predictors of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample. Arch Womens Ment Health. 2010;13(6): 485-94.
(2.) Nisar N, Zehra N, Haider G, Munir AA, Sohoo NA. Frequency, intensity and impact of premenstrual syndrome in medical students. J Coll Physicians Surg Pak. 2008;18(8):481-4.
(3.) Silva CM, Gigante DP, Carret ML, Fassa AG. [Population study of premenstrual syndrome]. Rev Saude Publica. 2006;40(1):47-56. Portuguese.
(4.) Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med. 2002;32(1):119-32.
(5.) Potter J, Bouyer J, Trussell J, Moreau C. Premenstrual syndrome prevalence and fluctuation over time: results from a French population-based survey. J Womens Health (Larchmt). 2009;18(1):31-9.
(6.) Freeman MP. Screening and treatment for women with mood disorders associated with reproductive events. J Clin Psychiatry. 2007;68(12):1946.
(7.) Fujii H, Sakai R, Masatsugu A, Ohta M, Matsumoto T, Doi T, et al. Case of premenstrual syndrome inducing monthly episodes of vesiculobullous eruptions on the face. J Dermatol. 2008;35(4):246-7.
(8.) Pakgohar M, Ahmadi M, Salehi surmaghi MH, Mehran A, Akhondzadeh Sh. [Effect of Hypericum perforatum L. for treatment of premenstrual syndrome]. J Med Plants. 2005;4(3):33-42. Persian.
(9.) Bertone-Johnson ER. Vitamin D and the occurrence of depression: causal association or circumstantial evidence? Nutr Rev. 2009;67(8):481-92.
(10.) Landen M, Erlandsson H, Bengtsson F, Andersch B, Eriksson E. Short onset of action of a serotonin reuptake inhibitor when used to reduce premenstrual irritability. Neuropsychopharmacology. 2009;34(3):585-92.
(11.) Salehi L, Salehi F. [The effect of pyridoxine (vit B6) on premenstrual syndrome]. J kordestan Univ Med Sci. 2007;2(3):32-9. Persian.
(12.) Studd J, Panay N. Are oestrogens useful for the treatment of depression in women? Best Pract Res Clin Obstet Gynaecol. 2009;23(1):63-71.
(13.) peroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. 7th ed. Philadelphia: Lippincott Williams & Wilkins; c2005. Chapter 14, Menstrual Disorders; p. 531-571 .
(14.) Jarvis CI, Lynch AM, Morin AK. Management strategies for premenstrual syndrome/premenstrual dysphoric disorder. Ann Pharmacother. 2008;42 (7):967-78.
(15.) Segebladh B, Borgstrom A, Nyberg S, Bixo M, Sundstrom-Poromaa I. Evaluation of different addback estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. Am J Obstet Gynecol. 2009;201(2):139.e1-8.
(16.) Yazdani M, Shahriyary M, Hamedi B. [Comparison of fennel versus placebo on dysmenorrhea and PMS]. J Hormozgan Univ Med Sci. 2004;8(1):57-61. Persian.
(17.) Doll M. [The premenstrual syndrome: effectiveness of Vitex agnus castus]. Med Monatsschr Pharm. 2009;32(5):186-91.German.
(18.) Jing Z, Yang X, Ismail KM, Chen X, Wu T. Chinese herbal medicine for premenstrual syndrome. Cochrane Database Syst Rev. 2009;(1): CD006414.
(19.) He Z, Chen R, Zhou Y, Geng L, Zhang Z, Chen S, et al. Treatment for premenstrual syndrome with Vitex agnus castus: A prospective, randomized, multi-center placebo controlled study in China. Maturitas. 2009;63(1):99-103.
(20.) Sadraei H, Asghari Gh, Yaghoubi Kh. [Study of the effect of hydro-Alcoholic and essential oil of Echinophora Platyloba on rat isolated ileum contractions in vitro].J Res Med Sci. 2003;7(Suppl 2):150-5. Persian.
(21.) Avijgan M, Saadat M, Nilforooshzadeh MA, Hafizi M. [Anti fungal effect of Echinophora platyloba extract on some common dermathophytes]. J Med Plants. 2006;5(18):10-6. Persian.
(22.) Avijgan M, Mahboubi M, Darabi M, Kasaiyan N. [Anti candidal activity of Echinophora platyloba against candida albicans and comparison with Amphotricin]. J Med Plants. 2009;8(30):36-43. Persian.
(23.) Moura LS, Carvalho JR, Stefanini MB, Ming LC, Meireles MAA. Supercritical fluid extraction from fennel (Foeniculum vulgare): global yield, composition and kinetic data. J Supercrit Fluids. 2005; 35(3):212-9.
(24.) Birdane FM, Cemek M, Birdane YO, Gilpin I, Biiyiikokuroglu ME. Beneficial effects of Foeniculum vulgare on ethanol-induced acute gastric mucosal injury in rats. World J Gastroenterol. 2007;13(4):607-11.
(25.) Shams Ardekani MR, Haji Akhoondi A, Jamshidi AH, Abdi Kh. [The study of volatile oil of Foeniculum Vulgare Miller in their tissue culture and comparison with the whole plant]. J Med Plants. 2005;4(15): 80-73. Persian.
(26.) Torkzahrani Sh, Akhavan-Amjadi M, Mojab F, Alavi Majd H. Clinical effects of Foeniculum vulgare extract on primary dysmenorrhea. J Reprod Infertil. 2007;8(1):45-51.
(27.) Modaress Nejad V, Motamedi B, Asadi pour M. [Comparison between the Pain-Relief Effect of Fennel and Mefenamic Acid on Primary Dysmenorrhea]. J Rafsanjan Univ Med Sci. 2006;5(1):1-6. Persian.
(28.) Ostad SN, Soodi M, Shariffzadeh M, Khorshidi N, Marzban H. The effect of fennel essential oil on uterine contraction as a model for dysmenorrhea, pharmacology and toxicology study. J Ethnopharmacol. 2001;76(3):299-304.
(29.) Borenstein JE, Dean BB, Yonkers KA, Endicott J. Using the daily record of severity of problems as a screening instrument for premenstrual syndrome. Obstet Gynecol. 2007;109(5):1068-75.
(30.) Entezari M, Hashemi M, Ashki M, Ebrahimian S, Bayat M, Azizi Saraji AR, et al. Studying the Effect Echinophora Platyloba Extract on Bactira (Staphilococus aureus and Pseudomonas aeroginosa) and Fungi (Candidia albicans, Aspergilus flavus and Aspergilus niger) In Vitro. World J Med Sci. 2009;4(2):89-92.
(31.) Shahhosseini Z, Amin Qh, Salehi sormaghi MH, Danesh MM. [Double blind study of anti primary dysmenorrhea effects of Vitagnus]. J Mazandaran Univ Med Sci. 2005;15(50):15-21. Persian.
(32.) Agajani Delavar M, Nasiri F, Hoseini SH. [A double-blind placebo-controlled evaluation of Vitex agnus castus in premenstrual syndrome]. J Med Plants.2002;1(2):15-21. Persian.
(33.) Ozgoli G, Selselei EA, Mojab F, Majd HA. A randomized, placebo-controlled trial of Ginkgo biloba L. in treatment of premenstrual syndrome. J Altern Complement Med. 2009;15(8):845-51.
Masoumeh Delaram  *, Soleiman Kheiri , Mohammad Reza Hodjati 
--Department of Midwifery, Shahrekord University of Medical Sciences, Shahrekord, Iran
--Department of Biostatistics and Epidemiology, Shahrekord University of Medical Sciences, Shahrekord, Iran
--Department of Physiology, Shahrekord University of Medical Sciences, Shahrekord, Iran
* Corresponding Author:
Masoumeh Delaram, Midwifery Departement, Shahrekord University of Medical Sciences, Shahrekord, Iran
E-mail: masoumehdelaram@ yahoo.com
Received: Nov. 16, 2010
Accepted: Mar. 14, 2011
Table 1. The demographic characteristics of the participants Group Echinophora-platyloba Characteristics M [+ or -] SD Age (year) 20.3 [+ or -] 1.6 Body mass index (kg/m2) 20.7 [+ or -] 2.7 Age at menarche (year) 13.50 [+ or -] 1.52 Age at dysmenorrhea onset (year) 14.42 [+ or -] 1.87 Duration of menstruation (day) 6.26 [+ or -] 1.25 Group Fennel Characteristics M [+ or -] SD Age (year) 19.9 [+ or -] 1.01 Body mass index (kg/m2) 19.8 [+ or -] 4.59 Age at menarche (year) 14.10 [+ or -] 1.19 Age at dysmenorrhea onset (year) 15.32 [+ or -] 1.38 Duration of menstruation (day) 6.21 [+ or -] 1.19 Group Placebo P-Value Characteristics M [+ or -] SD Age (year) 20.4 [+ or -] 1.9 0.471 Body mass index (kg/m2) 19.7 [+ or -] 4.1 0.631 Age at menarche (year) 14.12 [+ or -] 1.18 0.147 Age at dysmenorrhea onset (year) 15.33 [+ or -] 1.46 0.063 Duration of menstruation (day) 6.98 [+ or -] 1.34 0.058 The scores related to symptoms of PMS and the total mean of PMS have been presented in Table 2 Table 2. Comparison of PMS scores in echinophora-platyloba, fennel and placebo groups Treatment group E-chinophora- Fennel platyloba PMS Symptoms (before and M [+ or -] SD M [+ or -] SD after the intervention Anxiety Before 24.3 [+ or -] 5.1 22.8 [+ or -] 6.2 After 12.00 [+ or -] 4.3 14.1 [+ or -] 6.1 Reduction 12.3 [+ or -] 4.7 8.7 [+ or -] 4.6 Depression Before 28.9 [+ or -] 6.8 28.8 [+ or -] 9.4 After 14.0 [+ or -] 6.1 17.8 [+ or -] 9.0 Reduction 15.9 [+ or -] 5.9 * 11.0 [+ or -] 5.5 Emotional Before 18.4 [+ or -] 6.3 20.0 [+ or -] 6.4 After 10.3 [+ or -] 6.3 12.7 [+ or -] 5.3 Reduction 9.3 [+ or -] 5.9* 7.6 [+ or -] 4 * Fluid Retention Before 19.0 [+ or -] 7.0 20.5 [+ or -] 7.0 After 9.5 [+ or -] 6.5 13.6 [+ or -] 5.5 Reduction 10.5 [+ or -] 6.4 * 6.9 [+ or -] 5.7 Somatic Before 10.1 [+ or -] 4.4 9.3 [+ or -] 4.5 After 4.2 [+ or -] 4.5 5.9 [+ or -] 3.6 Reduction 6.0 [+ or -] 4.2 3.5 [+ or -] 3.1 Total score of PMS Before 100.8 [+ or -] 22.1 101.0 [+ or -] 27.2 After 49.7 [+ or -] 23.1 64.4 [+ or -] 27.5 Reduction 55.3 [+ or -] 18.5 * 38.7 [+ or -] 16.1 * Treatment group Placebo P-Value PMS Symptoms (before and M [+ or -] SD after the intervention Anxiety Before 23.9 [+ or -] 6.0 0.72 After 23.4 [+ or -] 5.5 0<0.001 Reduction 0.4 [+ or -] 3.1 0<0.001 Depression Before 28.8 [+ or -] 6.7 0.95 After 21.2 [+ or -] 6.7 0.04 Reduction 8.9 [+ or -] 8.6 * 0.029 Emotional Before 21.8 [+ or -] 6.0 0.06 After 14.2 [+ or -] 8.0 0.23 Reduction 5.4 [+ or -] 7.5 * 0.29 Fluid Retention Before 20.1 [+ or -] 7.2 0.71 After 13.0 [+ or -] 6.1 0.06 Reduction 8.2 [+ or -] 6.7 * 0.15 Somatic Before 9.7 [+ or -] 3.8 0.73 After 6.4 [+ or -] 5.6 0.20 Reduction 2.8 [+ or -] 4.9 * 0.10 Total score of PMS Before 104.3 [+ or -] 19.5 0.58 After 79.1 [+ or -] 28 0.009 Reduction 25.5 [+ or -] 22.4 0<0.001 * The reason of difference in the reduction mean of premenstrual symptoms with the mean of symptoms before and after the intervention, is that, a number of participants didn't answer to some of questions after the intervention
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Original Article|
|Author:||Delaram, Masoumeh; Kheiri, Soleiman; Hodjati, Mohammad Reza|
|Publication:||Journal of Reproduction and Infertility|
|Date:||Sep 1, 2011|
|Previous Article:||Down-regulation of HLA-G attenuates cleavage rate in human triploid embryos.|
|Next Article:||An unusual etiology of spontaneous pyometra perforation; a case report.|